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treatment and survival. RESULTS: A total of 2484 patients in the linked database 
met the study criteria. Mean age was 56.9 (SD=14.4) and 63.7% were male. The 
mean Deyo Charlson Comorbidity Index score was 0.59 (SD=1.11) over the six 
month pre-index period (modified to exclude malignancy). Overall, median 
survival time was 976 days (95% confidence interval: 847, 1194). A greater 
proportion of women (75%) than men (67%) were alive 365 days after their index 
surgery. Survival time decreased steadily with age as 98% of patients age 19-34 
survived for at least 365 days after surgery compared to 95% for patients 35-44, 
84% for patients 45-54, 70% for patients 55-64 and 43% for patients over 65. Most 
patients (52.1%) received external beam radiation, while 42.2% received 
temozolomide, 5.4% received a carmustine wafer implant, 2.0% received 
chemotherapy (including bevacizumab) and 1.3% received stereotactic 
radiosurgery within 90 days of their index surgery. CONCLUSIONS: Linking 
claims and public death records provided results in large populations that were 
similar to those in clinical trials and observational literature, both in terms of 
survival and treatment patterns.  
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OBJECTIVES: The risk of nephrotoxicity with cisplatin may be lower when 
glomerular filtration rate (GFR) is used as eligibility criteria compared to serum 
creatinine (SCr), but the impact on survival remains unknown. The objective of 
this meta-analysis was to indirectly compare the relative risk (RR) of death at 
one year in trials using cisplatin for NSCLC when renal function was assessed 
using either SCr or GFR for eligibility criteria. METHODS: Randomized trials 
comparing cisplatin to non-cisplatin regimens from 1990-2010 were identified in 
PubMed. Included studies used SCr or GFR as inclusion criteria, reported 
incidence of WHO or NCI grade ≥3 nephrotoxicity, and reported survival rate. 
Review articles, observational and non-randomized studies, phase 1 trials, 
studies not reported in English or without a comparator group were excluded. 
The number of patients surviving at one year was calculated from one-year 
survival rates. RR of death for cisplatin versus non-cisplatin regimens was 
estimated using random effects methods with sub-group analyses performed on 
studies using SCr, GFR, or either SCr or GFR as eligibility criteria. RESULTS: The 
literature search identified 2,359 studies of which 17 met inclusion/exclusion 
criteria (N=4,177). Of these, 9 studies used SCr (N=2,685), 1 used GFR (N=111), and 
7 used SCr or GFR (N=1,381) for screening. Overall, RR of death at one year with 
cisplatin versus non-cisplatin treatment was 1.05 (95%CI 0.96-1.15, p=0.28). In 
sub-group analyses, RR was 1.15 (95%CI 0.98-1.34, p=0.08) for SCr, 0.90 (95%CI 
0.75-1.08, p=0.27) for GFR, and 1.00 (95%CI 0.92-1.09, p=0.95) for either SCr or GFR. 
RR of death when GFR was indirectly compared to SCr was 0.78 (95%CI 0.62-0.99, 
p=0.04). CONCLUSIONS: Using GFR as eligibility criteria for cisplatin treatment 
appeared to reduce the risk of death at one year compared to SCr. However, 
results should be interpreted cautiously as only one study using GFR was 
included.  
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OBJECTIVES: To determine the impact of hormone receptor status and HER2 on 
survival for patients with triple negative breast cancer. METHODS: Electronic 
medical records from a network of 9 hospitals were linked to female breast 
cancer patients who were diagnosed between 2007 and 2010 in Florida. Cox 
proportional hazards model was used to assess cause-specific survival. 
RESULTS: Two-year survival of the study population was 95.1%. Median follow-
up time for those who died due to breast cancer was 569 days. Log-rank test 
indicated survival functions between blacks and non-blacks were significantly 
different over time (p< 0.0001). KM survival curves revealed that survival 
probability among black was lower than that of non-blacks. Hazard of breast 
cancer death among patients with triple negative and patients with unknown 
triple negative status were 4.34 and 2.35 times that of non-triple negative 
patients. Death rate among blacks was 1.6 times than non-blacks over time. 
Other factors associated with an increased hazard over time were being 
diagnosed in regional stage or having unknown diagnosis stage, having poorly or 
un-differentiated tumor, being Medicare user, being single, with larger tumor 
size, and with more positive nodes detected. Immediately after diagnosis distant 
stage and more comorbidity conditions were associated with an elevated risk, 
whereas more lymph nodes examined was associated with reduced risk of breast 
cancer death. Effects of distant stage, total comorbidity, and total lymph nodes 
examined gradually attenuated over time. CONCLUSIONS: This study highlights 
the importance of improvement of care for patients with triple negative 
biomarkers.  
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OBJECTIVES: Joint guidelines recommend colorectal cancer (CRC) screening 
every 10 years in average-risk adults beginning at age 50 years including 
colonoscopy (CSPY) where proper bowel preparation is critical for quality 
screening. The aim of our analysis was to quantify the budget impact on US 
payers of introducing a dual-acting osmotic and stimulant laxative for bowel 
cleansing, sodium picosulfate/magnesium citrate ( P/MC) in individuals 65 years 
and older. METHODS: A decision analytic model was developed to estimate the 
impact on direct medical costs of P/MC utilization in CRC screening by CSPY (2% 
and 12% in years one and three, respectively). Standard clinical practice  
was represented through a decision tree based on clinical guidelines  
and included utilization of currently prescribed bowel cleansing products 
(MoviPrep, HalfLytely, SuPrep, 4L PEG). Data from RCTs were used to quantify the 
adequacy of bowel cleansing. Prep costs were based on 2012 wholesale 
acquisition costs. Costs of complete, incomplete and repeat colonoscopies were 
obtained from Medicare claims analyses. RESULTS: For every 100,000 individuals 
65 years of age and older who undergo colonoscopy, the use of P/MC 
demonstrated cost neutrality when used by 2% of subjects, yielding annual 
incremental savings of $86,555 ($213,016,329 before introduction vs. $212,929,775 
after introduction). If P/MC use increases to 12% in year three, the annual 
estimated incremental savings per 100,000 cases increased to $333,846. Cost 
savings are mainly due to a reduction in repeat colonoscopies (-$439,904 year 
one and -$572,792 year three). One-way sensitivity analysis demonstrated the 
model to be most sensitive to P/MC drug cost and adequacy of cleansing when 
using generic 4L PEG. CONCLUSIONS: The introduction of P/MC into CRC 
screening practice in a 65 year and older population is cost neutral from the US 
payer perspective with moderate cost savings which becomes greater with 
increased utilization.  
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OBJECTIVES: A recent phase III clinical trial, EURTAC, demonstrated that first-
line treatment with erlotinib significantly improved progression-free survival 
compared with standard chemotherapy in advanced non-small cell lung cancer 
(NSCLC) patients whose tumors harbored epidermal growth factor receptor 
(EGFR) mutations. We sought to estimate the budgetary impact of adding 
coverage for erlotinib in this patient population. METHODS: We developed a 
budget impact model from the U.S. health plan perspective to compare EGFR test 
guided treatment with erlotinib (erlotinib for EGFR-positive patients and 
standard chemotherapy for EGFR-negative patients), compared to treatment with 
the standard chemotherapy without testing. Standard chemotherapy included 
recommended chemotherapy regimens as defined by the National 
Comprehensive Care Network guidelines. The target population was estimated 
using data extracted from the SEER 17 registries. Treatment duration, dosage, 
and adverse event data were derived from clinical trial data and manufacturer 
prescribing information. Cost data were obtained from the Centers for Medicare 
and Medicaid Services payment rates, and drug costs were based on wholesale 
acquisition costs. Sensitivity analyses were conducted to assess uncertainty. 
RESULTS: Overall health plan expenditures increased by $0.031 per member per 
month (PMPM). This increase was largely attributable to increased drug costs for 
patients receiving erlotinib who experienced longer progression-free survival 
and treatment duration. EGFR test cost also contributed to the increased 
expenditures, whereas adverse event costs reduced the incremental 
expenditures. The most influential model parameters were drug cost and 
treatment duration, however the budget impact did not exceed $0.045 PMPM in 
the sensitivity analyses. CONCLUSIONS: EGFR testing and treatment with 
erlotinib in 1st line NSCLC likely results in a relatively small budget impact for 
U.S. health plans, while providing a personalized medicine approach to lung 
cancer treatment.  
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OBJECTIVES: To estimate the annual budget impact of drug treatment associated 
with treating cancer patients with anemia due to the effect of concomitant 
myelosuppressive chemotherapy (CIA) with erythropoiesis stimulating agents 
(ESAs), either darbepoetin alfa (DA) once every three weeks (Q3W) or epoetin alfa 
(EA) once every week (QW), for a large US health plan in 2010. METHODS: A 
retrospective database analysis of administrative claims data for US 
commercially-insured individuals from January 1, 2009 to December 31, 2010 was 
conducted to estimate prevalence of CIA among patients receiving 
chemotherapy treatment. Using this information, a patient database from a large 
US health plan was adjusted to estimate budget impact of ESA treatment on this 
patient population (1,755 patients each per DA and EA) in 2010. The analysis 
assumed: 1) a minimum of two additional months of chemotherapy and 2) that 
administration costs equal the sum of office visit and injection costs. The 2010 
Centers for Medicare and Medicaid Services reimbursement rates used were: 
average sales price +12% of $3.06/mcg (DA) and $10.23/1,000 IU (EA), office-based 
